Lastly, therapeutic interventions targeting lead-responsive signaling pathways, such as MAPK or COX-2, could be investigated in preclinical models of bladder cancer to determine if they hold promise for improving patient outcomes. This evidence concerns the gene PTGS2 and urinary bladder cancer.